OTC Monograph Purity Concern Among Problems Noted In US FDA FY21 Drug Quality Review

Data Point To More Recalls As Inspections Increase, Problems With Firms' Investigations

 
• By Bowman Cox and Malcolm Spicer
  
Results from FDA requests sent to 13 manufacturers of 15 commonly used OTC drugs for data on the state of organic impurity control for monograph products. • Source: Shutterstock

More from Regulation

More from Policy & Regulation